STORM Therapeutics’ METTL3 inhibitor moves closer to the clinic
First-in-class drug candidate selected for development
Read More
Tag: STORM Therapeutics
Cambridge Uni spin-off raises £12m for cancer therapeutics
Cambridge University spin-off Storm Therapeutics has secured £12 million in series ‘A’ funding to advance its work on targeting enzymes that modify RNA to generate novel cancer therapeutics.
Read More
- CERo reports encouraging early data from phase 1 trial of CER‑1236
- ENA Respiratory begins dosing in phase 2 study of INNA‑051 nasal spray
- Argo Biopharma doses first patient in phase 2b trial of BW‑20829
- Akari files new patent and advances second ADC targeting CEACAM5
- BioMed X launches kidney disease project in partnership with the government of Barbados
